News
Insmed’s drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed dipeptidyl peptidase 1 (DPP1) inhibitor and the first therapy for non-cystic ...
In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...
The US Food and Drug Administration approved New Jersey, USA-based Insmed’s (Nasdaq: INSM) fibrosis bronchiectasis (NCFB), a ...
Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...
BRIDGEWATER – Shares of Insmed, a pharmaceutical firm at the intersection of Route 202-206 and Allen Road, jumped 8% on the NASDAQ after the federal Food and Drug Administration approved the company's ...
Stocktwits on MSN7h
Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic
Insmed shares got a wave of bullish calls Tuesday after U.S. regulators cleared its new drug Brinsupri, the first treatment ...
The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...
The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated’s (NASDAQ:INSM) Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic ...
Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...
A first-in-class reversible dipeptidyl peptidase-1 (DPP-1) inhibitor, brensocatib addresses the underlying inflammatory ...
The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis ...
Brinsupri is the first approved therapy to address the underlying inflammatory process of non-cystic fibrosis bronchiectasis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback